EGLT - Egalet Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.29
+0.00 (+0.55%)
At close: 4:00PM EDT

0.29 0.00 (0.00%)
After hours: 5:43PM EDT

Stock chart is not supported by your current browser
Previous Close0.29
Open0.30
Bid0.28 x 1000
Ask0.32 x 4000
Day's Range0.28 - 0.30
52 Week Range0.26 - 1.59
Volume166,380
Avg. Volume682,389
Market Cap15.712M
Beta0.13
PE Ratio (TTM)N/A
EPS (TTM)-0.90
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of EGLT earnings conference call or presentation 8-Aug-18 12:30pm GMT

    Q2 2018 Egalet Corp Earnings Call

  • ACCESSWIRE14 days ago

    Egalet Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Egalet Corporation (NASDAQ: EGLT ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30:00 AM Eastern Time. ...

  • Associated Press14 days ago

    Egalet: 2Q Earnings Snapshot

    The Wayne, Pennsylvania-based company said it had a loss of 22 cents per share. Losses, adjusted for non-recurring costs, were 17 cents per share. The pain medicine maker posted revenue of $7.4 million ...

  • Egalet Reports Second Quarter 2018 Financial Results
    PR Newswire14 days ago

    Egalet Reports Second Quarter 2018 Financial Results

    --Improvements in formulary status for key products-- --Company to host conference call today at 8:30 AM EDT-- WAYNE, Pa. , Aug. 8, 2018 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), ...

  • Benzinga14 days ago

    Preview: Egalet's Q2 Earnings

    On Wednesday,  Egalet (NASDAQ: EGLT ) will release its latest earnings report. Check out Benzinga's report to understand the earnings report's implications. Earnings and Revenue Egalet EPS will likely ...

  • GlobeNewswire26 days ago

    Market Trends Toward New Normal in Egalet, PPG Industries, Synergy Pharmaceuticals, Equity Residential, Array BioPharma, and Holly Energy Partners — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, July 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Egalet ...

  • Egalet to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on August 8, 2018
    PR Newswire28 days ago

    Egalet to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on August 8, 2018

    WAYNE, Penn., July 25, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced that its second quarter 2018 financial results will be released on Wednesday, August 8, 2018. Interested parties may listen to the call via a live audio webcast which may be accessed by visiting Egalet's website. Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions.

  • ACCESSWIRE2 months ago

    Free Daily Technical Summary Reports on Dermira and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on DERM sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Daré Bioscience Inc. (NASDAQ: DARE), Dermira Inc. (NASDAQ: DERM), Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA), and Egalet Corp. (NASDAQ: EGLT).

  • Egalet Appoints Industry Veteran John Varian to Board of Directors
    PR Newswire2 months ago

    Egalet Appoints Industry Veteran John Varian to Board of Directors

    WAYNE, Pa., June 7, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced the appointment of John Varian to its board of directors. Over the past three decades, Mr. Varian has helped companies establish strategic direction, raise capital, launch pharmaceutical products, structure and negotiate corporate alliances, communicate with investors and execute business development transactions.

  • Egalet to Participate in Panels at 2018 BIO International Convention and JMP Life Sciences Conference
    PR Newswire3 months ago

    Egalet to Participate in Panels at 2018 BIO International Convention and JMP Life Sciences Conference

    WAYNE, Pa., June 4, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced Bob Radie, president and chief executive officer, will present in panels at two upcoming conferences in June. Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has three approved products: ARYMO® ER (morphine sulfate) extended-release tablets for oral use —CII, developed using Egalet's proprietary Guardian™ Technology, OXAYDO® (oxycodone HCI, USP) tablets for oral use only —CII and SPRIX® (ketorolac tromethamine) Nasal Spray.

  • Egalet Announces Large Regional Plan to Cover SPRIX® Nasal Spray
    PR Newswire3 months ago

    Egalet Announces Large Regional Plan to Cover SPRIX® Nasal Spray

    WAYNE, Pa. , May 29, 2018 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing ...

  • Breakeven On The Horizon For Egalet Corporation (NASDAQ:EGLT)
    Simply Wall St.3 months ago

    Breakeven On The Horizon For Egalet Corporation (NASDAQ:EGLT)

    Egalet Corporation’s (NASDAQ:EGLT): Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. The US$29.69M market-cap company’s loss lessens since it announcedRead More...

  • Zacks Small Cap Research3 months ago

    EGLT: Partnerships and Formulary Adds Impressive; Waiting for Revenue Catch Up

    Revenues increased 15% on prescription growth of 115%. The results were distinguished by a marked decline in expenses, particularly R&D costs as the company streamlines its structure to emphasize profitability. The company continues to develop partnerships and add products to preferred formulary positions.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of EGLT earnings conference call or presentation 8-May-18 12:30pm GMT

    Q1 2018 Egalet Corp Earnings Call

  • Associated Press3 months ago

    Egalet: 1Q Earnings Snapshot

    The Wayne, Pennsylvania-based company said it had a loss of 26 cents per share. The pain medicine maker posted revenue of $6.3 million in the period. The company's shares closed at 73 cents. A year ago, ...

  • Egalet Reports First Quarter 2018 Financial Results
    PR Newswire3 months ago

    Egalet Reports First Quarter 2018 Financial Results

    --Multiple advances in formulary status for key products-- --Realigned and re-focused sales force-- --Company to host conference call today at 8:30 AM EDT-- WAYNE, Pa. , May 8, 2018 /PRNewswire/ -- Egalet ...

  • PR Newswire4 months ago

    Egalet Announces National Pharmacy Benefit Manager to Cover SPRIX® Nasal Spray and ARYMO® ER

    --SPRIX Nasal Spray placed in preferred position-- --Plan covers 3.5 million member lives-- WAYNE, Pa. , May 7, 2018 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated ...

  • ACCESSWIRE4 months ago

    Egalet to Present at the 3rd Annual Disruptive Growth & Healthcare Conference

    WAYNE, PA / ACCESSWIRE / May 2, 2018 / Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced that Bob Radie, Egalet's president and chief executive officer, will present at the 3rd Annual Disruptive Growth & Healthcare Conference in New York City. The investor presentation will be audio webcast live and available for replay at Egalet's website at http://egalet.investorroom.com/eventsandwebcasts. Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions.

  • Egalet Presented Data at American Academy of Pain Medicine Examining the Potential of ARYMO® ER to Deter Opioid Abuse
    PR Newswire4 months ago

    Egalet Presented Data at American Academy of Pain Medicine Examining the Potential of ARYMO® ER to Deter Opioid Abuse

    WAYNE, Pa., April 30, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced data on ARYMO ER (morphine sulfate) extended-release (ER) tablets CII were presented in four poster presentations at the 34th Annual Meeting of the American Academy of Pain Medicine (AAPM) in Vancouver, Canada. The data support the need for a multifaceted approach including abuse-deterrent opioids such as ARYMO ER to address the prescription opioid misuse and abuse crisis. Arymo ER has physical and chemical properties expected to make abuse by injection difficult.

  • Egalet to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results on May 8, 2018
    PR Newswire4 months ago

    Egalet to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results on May 8, 2018

    WAYNE, Pa., April 24, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced that its first quarter 2018 financial results will be released on Tuesday, May 8, 2018. Interested parties may listen to the call via a live audio webcast which may be accessed by visiting Egalet's website. Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions.

  • ACCESSWIRE4 months ago

    Free Post Earnings Research Report: Egalet's Q4 Top-Line Growth Beat Estimates

    LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free earnings report on Egalet Corp. (NASDAQ: EGLT). The Company posted its financial results on March 12, 2018, for the fourth quarter of the fiscal year 2017 (Q4 FY17) and for the full fiscal year 2017 (FY17). The Company's quarterly total revenues grew on a y-o-y basis to outshine market forecasts.

  • Egalet Announces Two Large Northeast Regional Health Plans Placed ARYMO® ER in Preferred Formulary Position
    PR Newswire4 months ago

    Egalet Announces Two Large Northeast Regional Health Plans Placed ARYMO® ER in Preferred Formulary Position

    WAYNE, Pa., April 17, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced that two large Northeast regional health plans have placed ARYMO® ER (morphine sulfate) extended-release (ER) tablets for oral use only –CII in a preferred formulary position effective immediately. "Obtaining preferred coverage from two large Northeast regional plans that cover nearly a million member lives is a critical step to broadening access to ARYMO ER for those who might need this treatment option," said Patrick Shea, chief commercial officer of Egalet. Please see safety information on ARYMO ER, including the boxed warning and medication guide below.

  • Zacks Small Cap Research5 months ago

    EGLT: Costs Down, Revenues Up, Partnerships Expanding

    The results were distinguished by higher year over year gross margins and expense reductions. Fourth quarter revenues were $7.8 million compared to our $8.8 million estimate and adjusted loss per share of ($0.31) was ahead of our ($0.37) estimate on lower expenses. Fourth quarter operational expenses of $16 million were less than our estimates of $20 million.